Study for underrepresented senior scientists funding and career support
This trial is for early-to-mid career scientists (10 to 15 years after their terminal degree) who are from groups under-represented in senior faculty roles and who already have a funded major research grant (R01 or similar). It aims to support and study initiatives that may help more scientists reach senior faculty positions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 10 to 15 years since your terminal degree in your field
- You identify with an ethnicity, race, or gender that is under-represented in senior faculty roles
- You have at least one funded R01-level grant (or a similar level grant)
- You must meet all inclusion requirements to be considered
- You should not be less than 10 or more than 15 years past your terminal degree
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study simulates working and living in lunar habitats, spacecraft during transit, and Mars surface environments. Researchers are testing how equipment, living spaces, and work routines function in these extreme conditions by having participants work through realistic scenarios in controlled settings.
This study tests whether extra training and mentorship help nurse practitioners and physician assistants lead more cancer research studies at their own clinics. If you are an APP who wants to grow research at your practice, this program could give you the support you need.
This study tests whether extra support services help women of color with metastatic breast cancer. It aims to improve access to emotional, practical, and medical resources.
This study looks at barriers that minority people may face in anesthesia. It may help the team understand what changes could improve training and/or care for minority clinicians and learners.
This trial tests a new drug combination called VA against a standard chemotherapy (3+7) for older adults newly diagnosed with a type of AML that has changes in the NPM1 or IDH1/IDH2 genes. It aims to see which treatment works better and is safer.
This study tests a new therapy called MNV-201 for people with low-risk myelodysplastic syndromes (MDS) who have anemia and need regular blood transfusions. The goal is to see if this treatment can help reduce or stop the need for transfusions.
Hear when a new Lack of Diversity in Scientific Leadership trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.